Oxybenzone
Shade Uvaguard (oxybenzone) is a small molecule pharmaceutical. Oxybenzone was first approved as Shade uvaguard on 1992-12-07. It is used to treat photosensitivity disorders in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Octinoxate
+
Oxybenzone
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SHADE UVAGUARD | Bayer | N-020045 DISCN | 1992-12-07 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
aloe up natural lip ice sunscreen | OTC monograph not final | 2023-06-07 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | OXYBENZONE |
INN | oxybenzone |
Description | Oxybenzone is a hydroxybenzophenone that is benzophenone which is substituted at the 2- and 4-positions of one of the benzene rings by hydroxy and methoxy groups respectively. It has a role as a dermatologic drug, a protective agent, an ultraviolet filter, a xenobiotic and an environmental contaminant. It is a hydroxybenzophenone and a monomethoxybenzene. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C(=O)c2ccccc2)c(O)c1 |
Identifiers
PDB | — |
CAS-ID | 131-57-7 |
RxCUI | 32673 |
ChEMBL ID | CHEMBL1625 |
ChEBI ID | 34283 |
PubChem CID | 4632 |
DrugBank | DB01428 |
UNII ID | 95OOS7VE0Y (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 629 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
24 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more